Key facts
- Plexium’s last known valuation is $200.0M (Aug 2025).
- It has raised $225.1M across 2 recorded rounds; the latest was Later Stage VC ($60.1M) in Jul 2025.
- Notable investors include RA Capital Management, New Enterprise Associates, SoftBank Investment Advisers, Lux Capital, University of California — 18 tracked in total.
- Plexium has filed 1 Form D with the SEC, most recently Aug 2025 ($60.1M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Plexium
Funding rounds
2 roundsAbout Plexium
Developer of protein-degrading therapeutics designed to treat cancer and other serious diseases. The company identifies novel small molecules that redirect ligases to targets of interest or induce degradation of targets by directly binding to them, enabling the medical community to combat cancer and inflammatory diseases in an improved manner.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 52
- Website
- plexium.com/
- Ownership
- Privately Held (backing)
Plexium doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Plexium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Plexium in its N-PORT filings yet. We sweep new filings monthly.